Adverse Event Management: Amivantamab
Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, including prophylactic antibiotics, good skin hygiene, and insights from the phase 2 COCOON study, can help manage potential adverse effects and improve treatment outcomes.
Video content above is prompted by the following:
- What proactive prophylaxis strategies have you integrated into your practice for patients taking amivantamab?
- Prophylactic antibiotics
- Good skin hygiene
- Phase 2 COCOON study findings
Recent Videos
Related Content
Amivantamab/Lazertinib Maintains OS Benefit in EGFR+ NSCLC
January 15th 2025Article
During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung cancer in the second article of a 2-part series.
Read More
